JamesDuganMD

PubMed

• The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
  Jan S Moreb, Lori Lantos, Franklin Chen, Kathleen Elliott, James Dugan, Alan P Skarbnik, Patricia Lamont Kropf, Kimberly Ward> ;Transfusion and Apheresis Science. 2023 Dec 1
• 8 citations
  Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
  Allison H. West, Hayley Knollman, James Dugan, Donald Hedeker, Elisabeth A Handorf, Sarah M. Nielsen, Lisa Bealin, Lindsay G Goldblatt, Heather Willems, Mary B. Daly, ...> ;Cancer Medicine. 2019 Sep 1
• 26 citations
  Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders.
  James P Dugan, Carrie B. Coleman, Bradley M. Haverkos> ;Frontiers in Oncology. 2019 Mar 15
• 24 citations
  Enasidenib for the treatment of acute myeloid leukemia.
  James Dugan, Daniel A. Pollyea> ;Expert Review of Clinical Pharmacology. 2018 Jul 24
• 12 citations
  Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
  James P Dugan, Bradley M. Haverkos, Linda Villagomez, Ludmila Katherine Martin, Mark E. Lustberg, John T. Patton, Marisa F. Martin, Ying Huang, Gerard J. Nuovo, Fengti...> ;Clinical Cancer Research. 2018 Jul 15
• Join now to see all